These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37402097)

  • 1. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
    Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
    Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
    Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
    Eyerich K; Asadullah K; Pinter A; Weisenseel P; Reich K; Paul C; Sabat R; Wolk K; Eyerich S; Lauffer F; Angsana J; Taut FJH; Kohler K; Chen Y; Sendecki J; Leung MWL; Wegner S; Personke Y; Gomez M; Krüger N; Tabori S; Schäkel K
    JAMA Dermatol; 2024 Sep; 160(9):953-963. PubMed ID: 39083288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
    Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
    J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study.
    Gargiulo L; Ibba L; Cortese A; Toso F; Vignoli CA; Fiorillo G; Piscazzi F; Valenti M; Costanzo A; Narcisi A
    J Drugs Dermatol; 2024 Aug; 23(8):632-639. PubMed ID: 39093650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
    Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
    Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
    Schäkel K; Reich K; Asadullah K; Pinter A; Jullien D; Weisenseel P; Paul C; Gomez M; Wegner S; Personke Y; Kreimendahl F; Chen Y; Angsana J; Leung MWL; Eyerich K
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2016-2027. PubMed ID: 37262309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.